Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

BACKGROUND: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. METHODS: Pts with previously treated advanced or mRCC were eligible to receive...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Verzoni, Elena, Cartenì, Giacomo, Cortesi, Enrico, Giannarelli, Diana, De Giglio, Andrea, Sabbatini, Roberto, Buti, Sebastiano, Rossetti, Sabrina, Cognetti, Francesco, Rastelli, Francesca, Sobrero, Alberto, Turci, Daniele, Sternberg, Cora N., Porta, Camillo, Cappuzzo, Federico, Tortora, Giampaolo, Tassinari, Davide, Panni, Stefano, Pazzola, Antonio, Surico, Gianmarco, Raimondi, Alessandra, De Giorgi, Ugo, Procopio, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6448290/
https://ncbi.nlm.nih.gov/pubmed/30944023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0579-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados